目前 IIIA（N2）期非小细胞肺癌的治疗管理：围手术期免疫治疗和酪氨酸激酶抑制剂的作用。

Current Management of Stage IIIA (N2) Non-Small-Cell Lung Cancer: Role of Perioperative Immunotherapy, and Tyrosine Kinase Inhibitors.

机构信息

Section of Thoracic Surgery, Department of Surgery, University of Chicago Medicine, Room S-546/MC 5047, 5841 South Maryland Avenue, Chicago, IL 60637, USA.

出版信息

Thorac Surg Clin. 2023 May;33(2):189-196. doi: 10.1016/j.thorsurg.2023.01.006. Epub 2023 Feb 26.

DOI:10.1016/j.thorsurg.2023.01.006

PMID:37045488

Abstract

There have been numerous recent advances in the treatmetn of stage IIIA non-small cell lung cancer. The most significant involve the addition of targeted therapies adn immune checkpoint inhibitors into perioperative care. These exciting advances are improving survival in this challenging patient population, but some-decade old controveries around the definition of resectability, prognositic importance of tumor response to induction therapy, and the role of pneumonectomy persist.

摘要

近年来，III 期非小细胞肺癌的治疗取得了众多进展。最显著的进展涉及将靶向治疗和免疫检查点抑制剂纳入围手术期治疗。这些令人兴奋的进展改善了这一具有挑战性的患者群体的生存情况，但有关可切除性的定义、诱导治疗后肿瘤反应的预后重要性以及肺切除术的作用等数十年的争议仍然存在。